pyrroles has been researched along with Parkinsonian Disorders in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, JS; Hou, L; Jing, L; Li, S; Peng, B; Ruan, Z; Wang, Q; Zhang, D; Zhang, X; Zhao, J | 1 |
| Chang, SC; Dinakaran, T; Kim, HS; Kim, S; Lee, J; Lee, Y; Vijayaraj, K | 1 |
| Castro, AA; Lapa, FR; Matheus, FC; Prediger, RD; Santos, AR; Tasca, CI; Viola, GG; Wiemes, BP | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Brocco, M; Mela, F; Millan, MJ; Morari, M | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| García-Estévez, DA; Navarro, C; San Millán, B; Sogo, T | 1 |
| Dallemagne, P; Demotes-Mainard, J; Guillon, J; Hébert, G; Jarry, C; Léger, JM; Lisowski, V; Rault, S; Thé, C; Vidaillac, C | 1 |
| KRAPCHO, J; SZABO, A; WILLIAMS, J | 1 |
| ARCHIBALD, JL | 1 |
| Brotchie, JM; Crossman, AR; Millan, MJ; Nicholson, SL; Ravenscroft, P; Silverdale, MA | 1 |
| Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL | 1 |
13 other study(ies) available for pyrroles and Parkinsonian Disorders
| Article | Year |
|---|---|
Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model.
Topics: Aminopyridines; Animals; Cognitive Dysfunction; Insecticides; Male; Mice; Mice, Inbred C57BL; Microglia; Minocycline; Parkinsonian Disorders; Pyrroles; Rotenone | 2021 |
One-step construction of a molybdenum disulfide/multi-walled carbon nanotubes/polypyrrole nanocomposite biosensor for the ex-vivo detection of dopamine in mouse brain tissue.
Topics: Animals; Biosensing Techniques; Brain; Dielectric Spectroscopy; Disulfides; Dopamine; Electrochemical Techniques; Male; Mice; Mice, Inbred C57BL; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Molybdenum; Nanocomposites; Nanotechnology; Nanotubes, Carbon; Parkinsonian Disorders; Polymers; Pyrroles; Spectrum Analysis, Raman | 2017 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Atorvastatin; Brain; Cognition Disorders; Cytokines; Disease Models, Animal; Food Preferences; Heptanoic Acids; Male; Maze Learning; Mood Disorders; Motor Activity; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Social Behavior; Sucrose; Sweetening Agents; Swimming; Tyrosine 3-Monooxygenase | 2013 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome | 2010 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
[Myopathy due to deficiency of desaminase myoadenilate induced by atorvastatine].
Topics: Aged; Amino Acid Substitution; AMP Deaminase; Atorvastatin; Biopsy; Causality; Creatine Kinase, MM Form; Exercise Tolerance; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Mitochondria, Muscle; Models, Genetic; Muscle, Skeletal; Mutation, Missense; Myalgia; Organic Anion Transporters; Parkinsonian Disorders; Point Mutation; Polymorphism, Single Nucleotide; Purine-Pyrimidine Metabolism, Inborn Errors; Pyrroles; Ubiquinone | 2013 |
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.
Topics: Animals; Disease Models, Animal; Indans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Pyrroles; Stereoisomerism; Structure-Activity Relationship | 2003 |
SYNTHESIS OF SUBSTITUTED 2-PHENYL-1,4-BENZOTHIAZIN-3(4H)-ONES AND THEIR ACTIVITY AS INHIBITORS OF 1,4-DIPYRROLIDINO-2-BUTYNE.
Topics: Alkynes; Animals; Chemistry, Pharmaceutical; Mice; Parasympatholytics; Parkinsonian Disorders; Pharmacology; Pyrroles; Research; Tremor | 1963 |
IMPROVED SYNTHESIS OF OXOTREMORINE.
Topics: Chemistry, Pharmaceutical; Oxotremorine; Parasympatholytics; Parkinsonian Disorders; Pyrroles; Research; Tremor | 1965 |
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indoles; Levodopa; Parkinsonian Disorders; Pyrroles; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2004 |
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate | 1999 |